AstraZeneca and the Broad Institute Collaborate
News Sep 11, 2012
AstraZeneca and the Broad Institute in Cambridge, Massachusetts announced a collaboration to identify new chemical compounds targeting bacterial and viral infections that could speed the development of new antibacterial and antiviral drugs.
Bacterial and viral infections remain a significant global health concern; according to the World Health Organisation’s ‘Global Burden of Disease’ report, infectious and parasitic diseases are the world’s second-largest leading cause of death and disability, and the growth of antibiotic-resistant “superbugs” that evade existing treatments is on the rise. However, few pharmaceutical companies are conducting research in this area. Only two new classes of antibiotics have been introduced to the market in the past 30 years.
While the medical need to treat severe infections remains very high, the identification of high-quality lead compounds for drug development is a significant challenge. Under the two-year collaboration announced today, the two organizations will work together to address this challenge by bringing together deep expertise in bacterial genomics and biochemistry with a unique collection (or “library”) of chemical compounds and chemical screening capabilities.
The chemical library, created at the Broad Institute, comprises 100,000 customized molecules known as Diversity-Oriented Synthesis (DOS) compounds. It is designed to contain molecular shapes and structures not found anywhere else that can hit even the most challenging biological targets. Under the agreement, screening and hit-to-lead chemistry will take place in the Broad’s Chemical Biology Platform and AstraZeneca will optimize, develop and commercialize potential compounds from identified, high-quality leads.
Dr. Michael Foley, director of the Broad Institute’s Chemical Biology Platform said: “We are thrilled to be working together with AstraZeneca on this project, which is closely aligned with the Broad Institute’s mission to propel the understanding and treatment of human disease. The Broad is one of the few places that has made a meaningful investment in new chemistry in the last five years, and we welcome this remarkable opportunity to harness that investment to improve human health.”
Dr. Manos Perros, vice president and head of the AstraZeneca Infection Innovative Medicines Unit said: “We believe new and collaborative approaches between the private and public sectors will help speed the discovery and development of new treatments, particularly for antibiotic-resistant infections. We are very pleased to work hand in hand with the Broad Institute to combine our unique resources and strong histories in innovation, discovery and development to speed advancements in treatments for infections. Through this collaboration we have already identified several new potential projects to pursue.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE